Skip to content
value.today

NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. is listed today as Stablecoin Development Corp: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 11 other private sales on record. Open the number of investors for the round's details.

Funding rounds of NovaBay Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2026$134 MPrivate placement after listing$50 to $250 million

NovaBay Pharmaceuticals, Inc.: Private sale, Jan 2026

Investors in this round

4 investors had bought by the notice of Jan 27, 2026: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$134 M of $134 M offered
Smallest investment taken
$25,000,000
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael John Kazley · Executive Officer, Director · Chief Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tommy Law, Chief Financial Officer. Newest notice filed Jan 27, 2026. Read the notice at the SEC.

optionsSEC
May 2023$3 MPrivate placement after listing$2 to $10 million

NovaBay Pharmaceuticals, Inc.: Private sale, May 2023

Investors in this round

5 investors had bought by the notice of May 18, 2023: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$240,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Audrey Kunin · Executive Officer, Director · CHIEF PRODUCT OFFICER
  • Jeffrey Kunin · Executive Officer · PRESIDENT, DERMADOCTOR, LLC
  • Justin Hall · Executive Officer, Director · CEO AND GENERAL COUNSEL
  • Tommy Law · Executive Officer · INTERIM CFO
  • Julie Garlikov · Director
  • Mijia (Bob) Wu · Director
  • Paul Freiman · Director
  • Swan Sit · Director
  • Yenyou (Jeff) Zheng · Director
  • Yongxiang (Sean) Zheng · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LADENBURG THALMANN & CO. INC. (CRD 505) · New York, New YorkSold in NV, NY

Signed by Justin Hall, Ceo and general counsel. Newest notice filed May 18, 2023. Read the notice at the SEC.

debt, optionsSEC
Sep 2022$3 MPrivate placement after listing$2 to $10 million

NovaBay Pharmaceuticals, Inc.: Private sale, Sep 2022

Investors in this round

4 investors had bought by the notice of Sep 23, 2022: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$260,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Jones · Executive Officer · CFO
  • Audrey Kunin · Executive Officer, Director · CHIEF PRODUCT OFFICER
  • Jeffrey Kunin · Executive Officer · PRESIDENT, DERMADOCTOR, LLC
  • Justin Hall · Executive Officer, Director · CEO AND GENERAL COUNSEL
  • Julie Garlikov · Director
  • Mijia (Bob) Wu · Director
  • Paul Freiman · Director
  • Swan Sit · Director
  • Yenyou (Jeff) Zheng · Director
  • Yongxiang (Sean) Zheng · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LADENBURG THALMANN & CO. INC. (CRD 505) · New York, New YorkSold in NV, NY

Signed by Justin Hall, Ceo and general counsel. Newest notice filed Sep 23, 2022. Read the notice at the SEC.

equity, optionsSEC
Sep 2022$2 MPrivate placement after listing$2 to $10 million

NovaBay Pharmaceuticals, Inc.: Private sale, Sep 2022

Investors in this round

9 investors had bought by the notice of Sep 23, 2022: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$165,240
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Jones · Executive Officer · CFO
  • Audrey Kunin · Executive Officer, Director · CHIEF PRODUCT OFFICER
  • Jeffrey Kunin · Executive Officer · PRESIDENT, DERMADOCTOR, LLC
  • Justin Hall · Executive Officer, Director · CEO AND GENERAL COUNSEL
  • Julie Garlikov · Director
  • Mijia (Bob) Wu · Director
  • Paul Freiman · Director
  • Swan Sit · Director
  • Yenyou (Jeff) Zheng · Director
  • Yongxiang (Sean) Zheng · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LADENBURG THALMANN & CO. INC. (CRD 505) · New York, New YorkSold in IL, KY, NV, NY

Signed by Justin Hall, Ceo and general counsel. Newest notice filed Sep 23, 2022. Read the notice at the SEC.

equity, optionsSEC
Nov 2021$15 MPrivate placement after listing$10 to $50 million

NovaBay Pharmaceuticals, Inc.: Private sale, Nov 2021

Investors in this round

7 investors had bought by the notice of Nov 17, 2021: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew M. Jones · Executive Officer · CHIEF FINANCIAL OFFICER
  • Audrey M. Kunin · Executive Officer · CHIEF PRODUCT OFFICER, DERMADOCTOR, LLC
  • Jeffrey M. Kunin · Executive Officer · PRESIDENT, DERMADOCTOR, LLC
  • Justin M. Hall · Executive Officer, Director · CHIEF EXECUTIVE OFFICER AND GENERAL COUNSEL
  • Mijia (Bob) E. Wu · Director
  • Paul E. Freiman · Director
  • Swan E. Sit · Director
  • Xinzhou (Paul) E. Li · Director
  • Yenyou (Jeff) E. Zheng · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New YorkSold in NY

Remarks in the notice

  • On a merger: “A PORTION OF THE PROCEEDS RAISED THROUGH THIS OFFERING WERE USED TO FUND THE PURCHASE PRICE FOR AN ALL CASH ACQUISITION BY THE COMPANY OF DERMADOCTOR, LLC.”

Signed by Justin M. Hall, CEO and General Counsel. Newest notice filed Nov 17, 2021. Read the notice at the SEC.

equity, optionsSEC
Aug 2019$3 MPrivate placement after listing$2 to $10 million

NovaBay Pharmaceuticals, Inc.: Private sale, Aug 2019

Investors in this round

3 investors had bought by the notice of Aug 26, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$162,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Raleigh · Executive Officer · CHIEF FINANCIAL OFFICER
  • Justin Hall · Executive Officer · CHIEF EXECUTIVE OFFICER
  • Gail Maderis · Director
  • Mijia (Bob) Wu · Director
  • Paul Freiman · Director
  • Todd Zavodnick · Director
  • Xiaopei (Ray) Wang · Director
  • Xinzhou (Paul) Li · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • CHINA KINGTON ASSET MANAGEMENT CO. LTD · Shanghai, ChinaSold in no state named, and outside the US

Signed by Justin Hall, President & chief execuitive officer and general counsel. Newest notice filed Aug 26, 2019 (1 amendment). Read the notice at the SEC.

equitySEC
Jun 2019$2 MPrivate placement after listing$2 to $10 million

NovaBay Pharmaceuticals, Inc.: Private sale, Jun 2019

Investors in this round

3 investors had bought by the notice of Jul 3, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$144,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jason Raleigh · Executive Officer · CHIEF FINANCIAL OFFICER
  • Justin Hall · Executive Officer · CHIEF EXECUTIVE OFFICER
  • Gail Maderis · Director
  • Mark Sieczkarek · Director
  • Mijia (Bob) Wu · Director
  • Paul Freiman · Director
  • Todd Zavodnick · Director
  • Xinzhou (Paul) Li · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • CHINA KINGTON ASSET MANAGEMENT CO. LTD. · Shanghai, ChinaSold in no state named, and outside the US

Signed by Justin Hall, President & chief executive officer and general counsel. Newest notice filed Jul 3, 2019. Read the notice at the SEC.

equitySEC
Feb 2018$6 MPrivate placement after listing$2 to $10 million

NovaBay Pharmaceuticals, Inc.: Private sale, Feb 2018

Investors in this round

1 investor had bought by the notice of Feb 14, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$359,040
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John J. McGovern · Executive Officer
  • Justin M. Hall · Executive Officer
  • Lewis J. Stuart · Executive Officer
  • Mark M. Sieczkarek · Executive Officer, Director
  • Gail J. Maderis · Director
  • Mijia (Bob) M. Wu · Director
  • Paul E. Freiman · Director
  • Todd J. Zavodnick · Director
  • Xiaoyan (Henry) J. Liu · Director
  • Xinzhou (Paul) E. Li · Director
  • Yonghao (Carl) J. Ma · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • China Kington Asset Management Co. Ltd. · Shanghai, ChinaSold in no state named, and outside the US

Signed by Justin M. Hall, SVP, General Counsel and Secretary. Newest notice filed Feb 14, 2018. Read the notice at the SEC.

equitySEC
May 2016$8 MPrivate placement after listing$2 to $10 million

NovaBay Pharmaceuticals, Inc.: Private sale, May 2016

Investors in this round

9 investors had bought by the notice of May 20, 2016: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $12 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$618,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Justin M. Hall · Executive Officer
  • Mark M. Sieczkarek · Executive Officer, Director
  • Thomas J. Paulson · Executive Officer
  • Gail J. Maderis · Director
  • Mijia (Bob) M. Wu · Director
  • Paul E. Freiman · Director
  • T. Alex McPherson · Director
  • Todd Alex Zavodnick · Director
  • Xiaoyan (Henry) Alex Liu · Director
  • Xinzhou (Paul) E. Li · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • China Kington Asset Management Co. Ltd. · Shanghai, ChinaSold in no state named, and outside the US

Remarks in the notice

  • On fees: “No commissions were paid on sales to U.S. citizens or persons or entities domiciled within the United States.”
  • On the amounts: “$1,491,000 of securities were or will be offered and sold within the United States, and $10,300,000 of securities were or will be offered and sold in non-U.S jurisdictions.”

Signed by Justin Hall, Senior Vice President, General Counsel. Newest notice filed May 20, 2016. Read the notice at the SEC.

equity, optionsSEC
Feb 2016$3 MPrivate placement after listing$2 to $10 million

NovaBay Pharmaceuticals, Inc.: Private sale, Feb 2016

Investors in this round

3 investors had bought by the notice of Feb 26, 2016: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$155,479
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Justin M. Hall · Executive Officer
  • Mark M. Sieczkarek · Executive Officer, Director
  • Roy J. Wu · Executive Officer
  • Thomas J. Paulson · Executive Officer
  • Gail J. Maderis · Director
  • Massimo Alex Radaelli · Director
  • Mijia Alex Wu · Director
  • Paul E. Freiman · Director
  • T. Alex McPherson · Director
  • Xiaoyan Alex Liu · Director
  • Xinzhou (Paul) E. Li · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • China Kington Asset Management Co. Ltd. · Shanghai, ChinaSold in no state named, and outside the US

Remarks in the notice

  • On fees: “No commissions were paid on sales to U.S. citizens or persons or entities domiciled within the United States.”
  • On the amounts: “$239,489.17 of securities were offered and sold within the United States, and $2,591,314.80 of securities were offered and sold in non-U.S. jurisdictions.”

Signed by Thomas J. Paulson, Chief Financial Officer. Newest notice filed Feb 26, 2016. Read the notice at the SEC.

equitySEC
Mar 2015$27 MPrivate placement after listing$10 to $50 million

NovaBay Pharmaceuticals, Inc.: Private sale, Mar 2015

Investors in this round

21 investors had bought by the notice of Jun 4, 2015: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for NovaBay Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Common Stock and Warrants to Purchase Common Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$215,500
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ramin (Ron) Najafi · Executive Officer, Director
  • Thomas E. Paulson · Executive Officer
  • Charles Cashion · Director
  • Gail E. Maderis · Director
  • Mark E. Sieczkarek · Director
  • Massimo E. Radaelli · Director
  • Paul E. Freiman · Director
  • T. Alex E. McPherson · Director
  • Tony E. Wicks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC · New York, New YorkSold in CA, IL, NY, TX

Signed by Thomas Paulson, Cfo. Newest notice filed Jun 4, 2015 (1 amendment). Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • NovaBay Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2026).

    SEC Form D · Jan 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2026

Products and services#

No products or services of NovaBay Pharmaceuticals, Inc. are on record.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in NovaBay Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
David E. LazarPersonnot statednot statedHeld Series D preferred stock, 10% owner, director (Form 3, 2025)SEC Form 3
Framework Ventures IV GP LLCVenture capitalnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Framework Ventures IV L.P.Venture capitalnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2025)SEC Form 3
Framework Ventures Management LLCVenture capitalnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2025)SEC Form 3
R01 Capital LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2025)SEC Form 3
R01 Capital Manager LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2025)SEC Form 3
R01 Fund LPFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2025)SEC Form 3

Largest shareholders today

Institutions holding Stablecoin Development Corp shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by NovaBay Pharmaceuticals, Inc.
NameRoleNamed in
Michael John KazleyChief Executive OfficerJan 2026
Audrey KuninCHIEF PRODUCT OFFICERMay 2023
Jeffrey KuninPRESIDENT, DERMADOCTOR, LLCMay 2023
Justin HallCEO AND GENERAL COUNSELMay 2023
Tommy LawINTERIM CFOMay 2023
Andrew JonesCFOSep 2022
Andrew M. JonesCHIEF FINANCIAL OFFICERNov 2021
Audrey M. KuninCHIEF PRODUCT OFFICER, DERMADOCTOR, LLCNov 2021
Jeffrey M. KuninPRESIDENT, DERMADOCTOR, LLCNov 2021
Justin M. HallCHIEF EXECUTIVE OFFICER AND GENERAL COUNSELNov 2021
Jason RaleighCHIEF FINANCIAL OFFICERAug 2019
John J. McGovernExecutive officerFeb 2018
Lewis J. StuartExecutive officerFeb 2018
Mark M. SieczkarekExecutive officerFeb 2018
Thomas J. PaulsonExecutive officerMay 2016
Roy J. WuExecutive officerFeb 2016
Ramin (Ron) NajafiExecutive officerJun 2015
Thomas E. PaulsonExecutive officerJun 2015
Michael John KazleyChief Executive OfficerJan 2026
Audrey KuninCHIEF PRODUCT OFFICERMay 2023
Julie GarlikovDirectorMay 2023
Justin HallCEO AND GENERAL COUNSELMay 2023
Mijia (Bob) WuDirectorMay 2023
Paul FreimanDirectorMay 2023
Swan SitDirectorMay 2023
Yenyou (Jeff) ZhengDirectorMay 2023
Yongxiang (Sean) ZhengDirectorMay 2023
Justin M. HallCHIEF EXECUTIVE OFFICER AND GENERAL COUNSELNov 2021
Mijia (Bob) E. WuDirectorNov 2021
Paul E. FreimanDirectorNov 2021
Swan E. SitDirectorNov 2021
Xinzhou (Paul) E. LiDirectorNov 2021
Yenyou (Jeff) E. ZhengDirectorNov 2021
Gail MaderisDirectorAug 2019
Todd ZavodnickDirectorAug 2019
Xiaopei (Ray) WangDirectorAug 2019
Xinzhou (Paul) LiDirectorAug 2019
Mark SieczkarekDirectorJul 2019
Gail J. MaderisDirectorFeb 2018
Mark M. SieczkarekDirectorFeb 2018

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.